Denmark-based biopharmaceutical company Orphazyme closed its series A round of funding on the 7th of September, raising €14m ($19.2m). The round was funded by Novo Ventures, the corporate venturing unit of Denmark-based healthcare company Novo, and venture capital firms Aescap Ventures and Sunstone Capital. Novo A/S acts as the holding company for its parent corporation, the Novo Group.

Novo Seeds, which acts as an early entry unit for the Novo Group as a whole, provided the initial seed funding for Orphazyme, in March 2010, following a pre-seed grant it had provided the year before. The amount Novo invested was undisclosed, though Sunstone later added $4.1m of seed financing in February of this year.

Founded in 2009, Orphazyme develops treatments for a family of genetic disorders known as lysosomal storage disorders. It plans to use the capital to advance its lead programa into clinical development.

Kim Dueholm, Partner at Novo Ventures,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?